Companies · Biotech / Pharma
PITTSBURGH · Biotech / Pharma · refined from filed group “Other”
Diligence memoA one-page analyst read on BlueSphere Bio, Inc. — recommendation, valuation, rhythm, risks.→BlueSphere Bio, Inc. has raised $56M over 2 rounds; too few niche peers to rank its valuation yet.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
BlueSphere Bio, Inc. is one of 227 Biotech / Pharma companies tracked from PITTSBURGH. By capital raised it ranks among the largest (ahead of 90% of sector peers), and among the largest by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.
Round size and date are reported; the stage label is inferred from round size (latest is Series C — a $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.
Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 90% of sector peers (real $). Modeled value above 96% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Life Biosciences LLC | Series C | $123.4M | $2.8B | 1.07× |
| Imago BioSciences, Inc. | Series C | $137.5M | $2.7B | 1.00× |
| BlueSphere Bio, Inc. this company | Series C | $55.6M | $1.5B | 0.55× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $10.0M | 2018-09-14 | $45.5M | $335.0M | 90% |
| Series C | $45.6M | 2020-12-18 | $304.2M | $1.5B | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Jeanne Cunicelli | — | 6 other | 2018-09 |
| David Apelian | — | 1 other | 2020-12 |
| Robert Lin | — | 1 other | 2020-12 |
| Tal Heppenstall | — | 1 other | 2018-09 |
| Alan Korman | — | — | 2020-12 |
| Mark Shlomchik | — | — | 2018-09 |
| Warren Shlomchik | — | — | 2018-09 |
BlueSphere Bio, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| NOLA PharmaHoldings, LLC | Biotech / Pharma | Series C | $48.1M | $448.1M | same sector · same stage |
| Belenos Biosciences, Inc. | Biotech / Pharma | Series C | $48.0M | $421.4M | same sector · same stage |
| Sudo Biosciences, Inc. | Biotech / Pharma | Series C | $73.1M | $685.8M | same sector · same stage |
| TwinStrand Biosciences, Inc. | Biotech / Pharma | Series C | $85.0M | $132.4M | same sector · same stage |
| Calypso Medical Technologies Inc | Other Health Care | Series C | $69.5M | $171.5M | network1 shared operator · same stage |
| Sherlock Biosciences, Inc. | Biotech / Pharma | Series C | $112.8M | $1.7B | same sector · same stage |
| Elephas Biosciences Corp | Biotech / Pharma | Series C | $113.7M | $560.6M | same sector · same stage |
| Generian Pharmaceuticals, Inc. | Biotech / Pharma | Series A | $13.0M | $435.2M | network1 shared operator · same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Asset Blue Pharmacy Services, Inc. | Biotech / Pharma | Series B | $104.7M | 84% |
| NJ BIO, Inc. | Biotech / Pharma | Series A | $55.0M | 83% |
| Bluestone Biomedical Group LLC | Other | Series A | $151.3M | 82% |
| BlueSphere Ventures Inc. | Other | Pre-Seed | $867K | 81% |
| Continuum Biosciences, Inc. | Biotech / Pharma | Pre-Seed | $25.6M | 81% |
| Outer Biosciences, LLC | Biotech / Pharma | Seed | $66.1M | 81% |
| Life Biosciences LLC | Biotech / Pharma | Series C | $2.8B | 81% |
| Ruby Bio, Inc. | Biotech / Pharma | Series A | $27.7M | 81% |
See where BlueSphere Bio, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at BlueSphere Bio, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.